VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Robert Motzer Reviews the Phase III COMPARZ Study

Robert J. Motzer, MD
Published: Tuesday, Mar 05, 2013

Robert J. Motzer, MD, attending physician, genitourinary oncology service, Memorial Sloan-Kettering Cancer Center, and professor of medicine, Weill Medical College, Cornell University, discusses the COMPARZ trial that compared pazopanib to sunitinib as a first-line treatment for patients with metastatic renal cell carcinoma (mRCC).

In the noninferiority study, 1110 patients with mRCC were randomized to receive pazopanib or sunitinib. The primary endpoint of progression-free survival (PFS) was statistically met, with a hazard radio of 1.047. Overall, these agents demonstrated similar antitumor activity, Motzer points out.

In a safety analysis, varying adverse events were reported for each agent. Treatment with pazopanib was commonly associated with liver enzyme elevation and weight loss. For sunitinib, patients reported fatigue, changes in taste, hand-foot syndrome, and thrombocytopenia.

An extensive analysis of quality of life (QoL) was conducted as part of the trial. Overall, 4 different questionnaires were used to assess 14 QoL domains. In total, in 11 of the 14 domains, patients reported a preference for pazopanib over sunitinib. Based on these scores, Motzer adds, QoL is better in those receiving pazopanib.

Robert J. Motzer, MD, attending physician, genitourinary oncology service, Memorial Sloan-Kettering Cancer Center, and professor of medicine, Weill Medical College, Cornell University, discusses the COMPARZ trial that compared pazopanib to sunitinib as a first-line treatment for patients with metastatic renal cell carcinoma (mRCC).

In the noninferiority study, 1110 patients with mRCC were randomized to receive pazopanib or sunitinib. The primary endpoint of progression-free survival (PFS) was statistically met, with a hazard radio of 1.047. Overall, these agents demonstrated similar antitumor activity, Motzer points out.

In a safety analysis, varying adverse events were reported for each agent. Treatment with pazopanib was commonly associated with liver enzyme elevation and weight loss. For sunitinib, patients reported fatigue, changes in taste, hand-foot syndrome, and thrombocytopenia.

An extensive analysis of quality of life (QoL) was conducted as part of the trial. Overall, 4 different questionnaires were used to assess 14 QoL domains. In total, in 11 of the 14 domains, patients reported a preference for pazopanib over sunitinib. Based on these scores, Motzer adds, QoL is better in those receiving pazopanib.




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x